Circulating tumor cells (CTCs) constitute a useful approach for personalized medicine. In prostate cancer, the expression of three tumor-associated transcripts, prostate-specific membrane antigen (PSMA), prostate-specific antigen (PSA) and epidermal growth factor receptor (EGFR), are often altered and used as biomarkers.

In addition, cell surface PSMA presents a unique target for treatment of patients early in their development of prostatic metastases.
How can you detect PSMA, PSA and EGFR in prostate cancer from blood? Learn more